Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival
2019-20 coronavirus outbreak
DOI:
10.1111/ene.14951
Publication Date:
2021-06-03T08:20:00Z
AUTHORS (12)
ABSTRACT
Myasthenia gravis (MG) patients could be a vulnerable group in the pandemic era of coronavirus 2019 (COVID-19) mainly due to respiratory muscle weakness, older age and long-term immunosuppressive treatment. We aimed define factors predicting severity COVID-19 MG risk exacerbation during COVID-19.We evaluated clinical features outcomes after 93 patients.Thirty-five (38%) had severe pneumonia we recorded 10 deaths (11%) COVID-19. Higher forced vital capacity (FVC) values tested before were shown protective against infection (95% CI 0.934-0.98) as well good control measured by quantified myasthenia score 1.047-1.232). Long-term chronic corticosteroid treatment worsened course 1.784-111.43) this impact was positively associated with dosage (p = 0.005). Treatment using azathioprine 0.448-2.935), mycophenolate mofetil 0.91-12.515) ciclosporin 0.029-2.212) did not influence treated rituximab high death caused 3.216-383.971). Exacerbation relatively rare (15%) remdesivir, convalescent plasma or favipiravir 0.885-10.87).As most important predictors identified unsatisfied condition lower FVC, previous especially higher doses, age, presence cancer, recent
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (36)
CITATIONS (58)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....